Press Releases
December 14, 2022
Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
November 28, 2022
Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
November 10, 2022
Panbela Provides Business Update and Reports Q3 2022 Financial Results
October 31, 2022
Panbela Schedules Conference Call on Nov 10, 2022 to Report 2022 Third Quarter Financial Results
November 10, 2022, 4:30 PM Eastern Time
Participant Numbers
Toll Free: 877-545-0523 / International: 973-528-0016
Participant Access Code: 598956
Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/46946
Conference Call Replay Information
Replay Number:
Toll Free: 877-481-4010 / International: 919-882-2331
Replay Passcode: 46946
Webcast Replay: https://www.webcaster4.com/Webcast/Page/2556/46946
September 30, 2022
Panbela Announces Pricing of Approximately $6 Million Public Offering
September 29, 2022
Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
August 15, 2022
Panbela Provides Business Update and Reports Q2 2022 Financial Results
August 11, 2022
Panbela Announces 1st Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
August 4, 2022
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
August 1, 2022